Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 Mar;39(3):289–295. doi: 10.1111/j.1365-2125.1995.tb04451.x

Pharmacokinetics and adverse reactions after a single dose of pentamidine in patients with Trypanosoma gambiense sleeping sickness.

U Bronner 1, L L Gustafsson 1, F Doua 1, O Ericsson 1, T Miézan 1, M Rais 1, L Rombo 1
PMCID: PMC1365006  PMID: 7619671

Abstract

1. Plasma concentrations of pentamidine were measured up to 1-8 months after a single 2 h i.v. infusion of 3.0 to 4.8 mg kg-1 pentamidine isethionate in 11 patients with late stage Trypanosoma gambiense sleeping sickness. 2. Maximum plasma drug concentrations varied between 713 and 2461 nmol 1-1. After termination of infusion, a rapid distribution phase over 10 min was followed by a slower distribution phase and an elimination phase prolonged over weeks to months. 3. The 'terminal' elimination rate constant could be determined in six patients and subsequent kinetic calculations showed a three to fourfold variation in plasma clearance and 'terminal' half-life (median 1126 (range 553-2036) ml min-1 and 265 (107-446) h, respectively). The median apparent volume of distribution (Vss) was 11,850 1. Renal clearance accounted for a median of 11% of total plasma clearance, indicating that metabolism is a major route of pentamidine elimination in man. 4. Side effects were few and mild and a slight or moderate decrease in blood pressure was the most common registered adverse reaction observed in four subjects. 5. The prolonged elimination of pentamidine seems inconsistent with the present recommended dosage regimen of pentamidine for treatment of trypanosomiasis of 7 to 10 parenteral doses given once daily or every second day.

Full text

PDF
289

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berger B. J., Naiman N. A., Hall J. E., Peggins J., Brewer T. G., Tidwell R. R. Primary and secondary metabolism of pentamidine by rats. Antimicrob Agents Chemother. 1992 Sep;36(9):1825–1831. doi: 10.1128/aac.36.9.1825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bronner U., Doua F., Ericsson O., Gustafsson L. L., Miézan T. W., Rais M., Rombo L. Pentamidine concentrations in plasma, whole blood and cerebrospinal fluid during treatment of Trypanosoma gambiense infection in Côte d'Ivoire. Trans R Soc Trop Med Hyg. 1991 Sep-Oct;85(5):608–611. doi: 10.1016/0035-9203(91)90364-5. [DOI] [PubMed] [Google Scholar]
  3. Cattand P., Miezan B. T., de Raadt P. Human African trypanosomiasis: use of double centrifugation of cerebrospinal fluid to detect trypanosomes. Bull World Health Organ. 1988;66(1):83–86. [PMC free article] [PubMed] [Google Scholar]
  4. Comtois R., Pouliot J., Vinet B., Gervais A., Lemieux C. Higher pentamidine levels in AIDS patients with hypoglycemia and azotemia during treatment of Pneumocystis carinii pneumonia. Am Rev Respir Dis. 1992 Sep;146(3):740–744. doi: 10.1164/ajrccm/146.3.740. [DOI] [PubMed] [Google Scholar]
  5. Conte J. E., Jr Pharmacokinetics of intravenous pentamidine in patients with normal renal function or receiving hemodialysis. J Infect Dis. 1991 Jan;163(1):169–175. doi: 10.1093/infdis/163.1.169. [DOI] [PubMed] [Google Scholar]
  6. Conte J. E., Jr, Upton R. A., Lin E. T. Pentamidine pharmacokinetics in patients with AIDS with impaired renal function. J Infect Dis. 1987 Dec;156(6):885–890. doi: 10.1093/infdis/156.6.885. [DOI] [PubMed] [Google Scholar]
  7. Conte J. E., Jr, Upton R. A., Phelps R. T., Wofsy C. B., Zurlinden E., Lin E. T. Use of a specific and sensitive assay to determine pentamidine pharmacokinetics in patients with AIDS. J Infect Dis. 1986 Dec;154(6):923–929. doi: 10.1093/infdis/154.6.923. [DOI] [PubMed] [Google Scholar]
  8. Donnelly H., Bernard E. M., Rothkotter H., Gold J. W., Armstrong D. Distribution of pentamidine in patients with AIDS. J Infect Dis. 1988 May;157(5):985–989. doi: 10.1093/infdis/157.5.985. [DOI] [PubMed] [Google Scholar]
  9. Ericsson O., Rais M. Determination of pentamidine in whole blood, plasma, and urine by high-performance liquid chromatography. Ther Drug Monit. 1990 Jul;12(4):362–365. doi: 10.1097/00007691-199007000-00011. [DOI] [PubMed] [Google Scholar]
  10. Helmick C. G., Green J. K. Pentamidine-associated hypotension and route of administration. Ann Intern Med. 1985 Sep;103(3):480–480. doi: 10.7326/0003-4819-103-3-480_1. [DOI] [PubMed] [Google Scholar]
  11. Lachaal M., Venuto R. C. Nephrotoxicity and hyperkalemia in patients with acquired immunodeficiency syndrome treated with pentamidine. Am J Med. 1989 Sep;87(3):260–263. doi: 10.1016/s0002-9343(89)80147-0. [DOI] [PubMed] [Google Scholar]
  12. Lidman C., Bronner U., Gustafsson L. L., Rombo L. Plasma pentamidine concentrations vary between individuals with Pneumocystis carinii pneumonia and the drug is actively secreted by the kidney. J Antimicrob Chemother. 1994 Apr;33(4):803–810. doi: 10.1093/jac/33.4.803. [DOI] [PubMed] [Google Scholar]
  13. Lumsden W. H., Kimber C. D., Evans D. A., Doig S. J. Trypanosoma brucei: Miniature anion-exchange centrifugation technique for detection of low parasitaemias: Adaptation for field use. Trans R Soc Trop Med Hyg. 1979;73(3):312–317. doi: 10.1016/0035-9203(79)90092-0. [DOI] [PubMed] [Google Scholar]
  14. Miézan T. W., Bronner U., Doua F., Cattand P., Rombo L. Long-term exposure of Trypanosoma brucei gambiense to pentamidine in vitro. Trans R Soc Trop Med Hyg. 1994 May-Jun;88(3):332–333. doi: 10.1016/0035-9203(94)90105-8. [DOI] [PubMed] [Google Scholar]
  15. Navin T. R., Fontaine R. E. Intravenous versus intramuscular administration of pentamidine. N Engl J Med. 1984 Dec 27;311(26):1701–1702. doi: 10.1056/nejm198412273112616. [DOI] [PubMed] [Google Scholar]
  16. Pattullo A. L., Meynard M., Bow E. J. Hematuria associated with pentamidine therapy for Pneumocystis carinii pneumonia. AIDS. 1992 Jun;6(6):595–597. [PubMed] [Google Scholar]
  17. Sands M., Kron M. A., Brown R. B. Pentamidine: a review. Rev Infect Dis. 1985 Sep-Oct;7(5):625–634. doi: 10.1093/clinids/7.5.625. [DOI] [PubMed] [Google Scholar]
  18. Shertzer H. G., Hall J. E., Seed J. R. Hepatic mixed-function oxidase activity in mice infected with Trypanosoma brucei gambiense or treated with trypanocides. Mol Biochem Parasitol. 1981 Aug;3(4):199–204. doi: 10.1016/0166-6851(81)90051-7. [DOI] [PubMed] [Google Scholar]
  19. Shuster M., Dunn M. Pentamidine and hematuria. Ann Intern Med. 1986 Jul;105(1):146–146. doi: 10.7326/0003-4819-105-1-146_1. [DOI] [PubMed] [Google Scholar]
  20. Tomson T., Svensson J. O., Hilton-Brown P. Relationship of intraindividual dose to plasma concentration of carbamazepine: indication of dose-dependent induction of metabolism. Ther Drug Monit. 1989 Sep;11(5):533–539. [PubMed] [Google Scholar]
  21. Waalkes T. P., Denham C., DeVita V. T. Pentamidine: clinical pharmacologic correlations in man and mice. Clin Pharmacol Ther. 1970 Jul-Aug;11(4):505–512. doi: 10.1002/cpt1970114505. [DOI] [PubMed] [Google Scholar]
  22. Western K. A., Perera D. R., Schultz M. G. Pentamidine isethionate in the treatment of Pneumocystis carinii pneumonia. Ann Intern Med. 1970 Nov;73(5):695–702. doi: 10.7326/0003-4819-73-5-695. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES